サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468084

コレラワクチン市場レポート：ワクチンタイプ、製品、エンドユーザー、地域別、2024～2032年

Cholera Vaccines Market Report by Vaccine Type, Product, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 138 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
コレラワクチン市場レポート：ワクチンタイプ、製品、エンドユーザー、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

コレラワクチンの世界市場規模は2023年に540万米ドルに達しました。今後、IMARC Groupは、2024～2032年の間に10％の成長率（CAGR）を示し、2032年までに市場は1,300万米ドルに達すると予測しています。コレラ予防に対する一般市民の意識の高まり、政府の積極的な取り組みと国際協力、ワクチン技術の継続的な進歩、旅行や貿易の急増、継続的な研究開発活動、世界ヘルスの重視は、市場成長を促進する要因の一部です。

コレラワクチンは、下痢を引き起こし、脱水症状や死に至ることもある細菌感染症コレラに対する防御を提供するために設計された医療介入です。コレラワクチンは、コレラの原因菌であるコレラ菌の不活化または弱毒化を組み合わせて開発されます。そのプロセスには、細菌を大量に増殖させ、病原性をなくし、ワクチンに製剤化することが含まれます。コレラワクチンの利点は、特に衛生状態や水供給が不十分な地域において、コレラの発生を予防するための積極的なアプローチを提供することです。コレラ菌を認識して闘う免疫システムの能力を強化することで、これらのワクチンは病気の重症度と期間を軽減することができます。さらに、地域社会や国境を越えたコレラ感染の減少にも貢献します。コレラワクチンには、主に経口剤と注射剤の2種類があります。

世界のコレラワクチン市場は、特にコレラが発生しやすい地域におけるコレラ予防とワクチン接種の重要性に対する意識の高まりの影響を受けています。さらに、ワクチン接種キャンペーンを通じてコレラの蔓延を抑制しようとする政府の取り組みや国際機関の努力は、市場拡大に極めて重要な役割を果たしています。さらに、ワクチン技術の進歩により、より効率的で費用対効果の高いワクチンが開拓され、市場の成長を後押ししています。さらに、旅行や国際貿易の頻度が高まるにつれ、旅行者が国境を越えてコレラ病を持ち運ぶ可能性があるため、コレラワクチン接種の必要性が高まっており、これが市場の成長を支えています。これに加えて、ワクチンの有効性と安全性を高めることを目的とした研究開発（R&D）活動の継続が、市場の成長に寄与しています。

コレラワクチン市場の動向と促進要因：

コレラ予防に対する意識の高まり

世界のコレラワクチン市場は、コレラ予防とワクチン接種の重要な役割をめぐる意識の高まりから大きな刺激を受けています。コレラ発生がもたらす壊滅的な影響について地域社会がより深く知るようになるにつれ、ワクチン接種を含む効果的な予防対策への需要が高まっています。このような意識の高まりは、公衆衛生キャンペーン、教育的イニシアティブ、コレラの影響とその蔓延を抑えるためのワクチン接種の重要性を強調するメディア報道によってもたらされることが多いです。この促進要因は、個人や地域レベルのワクチン接種への関心を喚起するだけでなく、政府、医療組織、国際機関がワクチン接種キャンペーンにリソースを割り当てることを促し、市場成長を後押しします。

政府のイニシアチブと国際的な取り組み

政府のイニシアティブや国際機関による協力的な取り組みは、世界のコレラワクチン市場の拡大に大きく貢献しています。コレラが発生しやすい地域の政府は、コレラがもたらす社会経済的負担を認識し、重要な予防戦略としてワクチン接種プログラムを優先しています。さらに、世界保健機関（WHO）やユニセフのような国際機関は、各国政府とパートナーシップを結び、ワクチン接種キャンペーンを支援するために技術的専門知識、資金、ワクチンの供給を提供しています。このような協調的なアプローチは、資源に乏しい地域でのワクチン入手を確実にするだけでなく、コレラワクチンの安定した需要を生み出すことで、市場成長のための環境も醸成しています。

ワクチン技術の進歩

ワクチン技術の進歩は、世界のコレラワクチン市場を前進させる上で極めて重要な役割を果たしています。ワクチンの有効性、安全性、製造プロセスの改善に焦点を当てた研究開発が行われ、より新しく効果的なコレラワクチンが市場に導入されています。このような進歩により、予防効果がより長く持続し、接種回数がより少なく、幅広い年齢層に適したワクチンの開発が可能になりました。さらに、経口ワクチンのようなワクチン投与メカニズムの革新は、特に医療のインフラが整っていない地域において、ワクチンの受容性を高め、投与を容易にすることに貢献しています。ワクチン技術の絶え間ない進化は、コレラワクチンの全体的な有効性を高めるだけでなく、医療プロバイダーや地域社会に疾病予防のためのより良い手段を提供することで、市場の成長を促進しています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 コレラワクチンの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：ワクチンタイプ別

  • 全細胞型V.コレラ菌O1と組み換えBサブユニット
  • キルド経口O1とO139

第7章 市場内訳：製品別

  • デュコラル
  • シャンコール
  • ヴァクソラ
  • ユビコールとユビコールプラス
  • その他

第8章 市場内訳：エンドユーザー別

  • 病院・クリニック
  • 研究・学術研究所
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Astellas Pharma Inc.
    • Celldex Therapeutics Inc.（Avant Immunotherapeutics Inc.）
    • Emergent BioSolutions Inc.
    • Eubiologics Co. Ltd.
    • Johnson & Johnson
    • Merck & Co. Inc
    • Pfizer Inc.
    • PharmaChoice Canada Inc
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited.
    • Valneva SE
図表

List of Figures

  • Figure 1: Global: Cholera Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Cholera Vaccines Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Cholera Vaccines Market: Breakup by Vaccine Type (in %), 2023
  • Figure 5: Global: Cholera Vaccines Market: Breakup by Product (in %), 2023
  • Figure 6: Global: Cholera Vaccines Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Cholera Vaccines Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Cholera Vaccines (Whole Cell V. Cholerae O1 with Recombinant B-Subunit) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Cholera Vaccines (Whole Cell V. Cholerae O1 with Recombinant B-Subunit) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Cholera Vaccines (Killed Oral O1 and O139) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Cholera Vaccines (Killed Oral O1 and O139) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Cholera Vaccines (Dukoral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Cholera Vaccines (Dukoral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Cholera Vaccines (Shanchol) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Cholera Vaccines (Shanchol) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Cholera Vaccines (Vaxchora) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Cholera Vaccines (Vaxchora) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Cholera Vaccines (Euvichol and Euvichol-Plus) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Cholera Vaccines (Euvichol and Euvichol-Plus) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Cholera Vaccines (Other Product) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Cholera Vaccines (Other Product) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Cholera Vaccines (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Cholera Vaccines (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Cholera Vaccines (Research and Academic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Cholera Vaccines (Research and Academic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Cholera Vaccines (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Cholera Vaccines (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Cholera Vaccines Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Cholera Vaccines Industry: SWOT Analysis
  • Figure 78: Global: Cholera Vaccines Industry: Value Chain Analysis
  • Figure 79: Global: Cholera Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cholera Vaccines Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cholera Vaccines Market Forecast: Breakup by Vaccine Type (in Million US$), 2024-2032
  • Table 3: Global: Cholera Vaccines Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 4: Global: Cholera Vaccines Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Cholera Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Cholera Vaccines Market: Competitive Structure
  • Table 7: Global: Cholera Vaccines Market: Key Players
目次
Product Code: SR112024A4973

The global cholera vaccines market size reached US$ 5.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.0 Million by 2032, exhibiting a growth rate (CAGR) of 10% during 2024-2032. The increasing public awareness of cholera prevention, robust government initiatives and international collaboration, continual advancements in vaccine technology, the surge in travel and trade, ongoing research and development activities, and the emphasis on global health are some of the factors fueling the market growth.

Cholera vaccines are medical interventions designed to provide protection against cholera, a bacterial infection that causes diarrhea and can lead to dehydration and even death. They are developed using a combination of inactivated or attenuated Vibrio cholerae bacteria, the causative agent of cholera. The process involves growing large quantities of the bacteria, rendering them non-virulent, and then formulating them into vaccines. The advantages of cholera vaccines are significant, such as they offer a proactive approach to preventing cholera outbreaks, particularly in regions with inadequate sanitation and water supplies. By bolstering the immune system's ability to recognize and fight the cholera bacteria, these vaccines can reduce the severity and duration of the illness. Moreover, they contribute to reducing the transmission of cholera within communities and across borders. Two main types of cholera vaccines include oral and injectable.

The global cholera vaccines market is influenced by the increasing awareness about cholera prevention and the importance of vaccination, especially in regions prone to outbreaks. Additionally, government initiatives and international organizations' efforts to control cholera's spread through vaccination campaigns play a pivotal role in market expansion. Moreover, advancements in vaccine technology, resulting in the development of more efficient and cost-effective vaccines, bolster market growth. Furthermore, the rising frequency of travel and international trade fosters the need for cholera vaccination, as travelers can potentially carry the disease across borders, which, in turn, is supporting the market growth. Besides this, ongoing research and development (R&D) activities aimed at enhancing vaccine efficacy and safety are contributing to the market growth.

Cholera Vaccines Market Trends/Drivers:

Increasing awareness and cholera prevention

The global cholera vaccines market experiences a significant impetus from the increasing awareness surrounding cholera prevention and the crucial role of vaccination. As communities become more informed about the devastating impact of cholera outbreaks, the demand for effective preventive measures, including vaccination, rises. This heightened awareness is often driven by public health campaigns, educational initiatives, and media coverage that highlight the consequences of cholera and the importance of vaccination in curbing its spread. This driver not only stimulates individual and community-level interest in vaccination but also encourages governments, healthcare organizations, and international bodies to allocate resources towards vaccination campaigns, propelling market growth.

Government initiatives and international efforts

Government initiatives and collaborative efforts by international organizations contribute significantly to the expansion of the global cholera vaccines market. Governments of cholera-prone regions recognize the socio-economic burden posed by cholera and prioritize vaccination programs as a crucial preventive strategy. Moreover, international organizations like the World Health Organization (WHO) and UNICEF engage in partnerships with governments, providing technical expertise, funding, and vaccine supply to support vaccination campaigns. This coordinated approach not only ensures vaccine accessibility in resource-constrained regions but also fosters a conducive environment for market growth by creating a steady demand for cholera vaccines.

Advancements in vaccine technology

Advancements in vaccine technology play a pivotal role in propelling the global cholera vaccines market forward. As research and development efforts focus on improving vaccine efficacy, safety, and production processes, newer and more effective cholera vaccines are introduced to the market. These advancements enable the creation of vaccines that offer longer-lasting protection, require fewer doses, and are suitable for a wider range of age groups. Additionally, innovations in vaccine delivery mechanisms, such as oral vaccines, contribute to increased vaccine acceptance and ease of administration, particularly in areas with limited healthcare infrastructure. The continuous evolution of vaccine technology not only enhances the overall effectiveness of cholera vaccines but also fuels market growth by providing healthcare providers and communities with better tools for disease prevention.

Cholera Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on vaccine type, product and end user.

Breakup by Vaccine Type:

Whole Cell V. Cholerae O1 with Recombinant B-Subunit

Killed Oral O1 and O139

Whole cell V. cholerae O1 with recombinant B-subunit dominates the market

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes whole cell V. cholerae O1 with recombinant B-subunit and killed oral O1 and O139. According to the report, whole cell V. cholerae O1 with recombinant B-subunit represented the largest segment.

The whole cell V. cholerae O1 with recombinant B-subunit segment is propelled by the comprehensive protection offered by whole-cell vaccines against cholera caused by V. cholerae O1. The inclusion of recombinant B-subunit enhances immunogenicity, bolstering the vaccine's efficacy in inducing protective immune responses. Additionally, the rising global awareness about cholera's impact on public health underscores the importance of advanced vaccines. Moreover, governmental initiatives and collaborations with international health organizations amplify the distribution and administration of these vaccines, especially in endemic regions. In line with this, ongoing research and development efforts continually refine vaccine formulations, ensuring optimal safety and effectiveness. Apart from this, the evolving landscape of international travel and trade heightens the demand for robust preventive measures, boosting the adoption of this segment.

Breakup by Product:

Dukoral

Shanchol

Vaxchora

Euvichol and Euvichol-Plus

Others

Dukoral dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes dukoral, shanchol, vaxchora, euvichol and euvichol-plus, and others. According to the report, dukoral represented the largest segment.

The dukoral segment is propelled by the surging awareness regarding the unique formulation of the product, encompassing both cholera and ETEC (enterotoxigenic Escherichia coli) antigens. Additionally, its established reputation for safety and efficacy, backed by rigorous clinical trials, instills confidence among healthcare professionals and recipients alike, boosting its adoption. Moreover, the expanding travel and tourism sector drives demand for dukoral, as it addresses the risk of cholera and ETEC infections associated with global mobility. Furthermore, its oral administration aligns with the preference for non-invasive vaccination methods, especially in regions with limited healthcare infrastructure. In line with this, ongoing research to refine dukoral's formulation and increase accessibility in underserved areas underscores its significance, solidifying its position as a driver in the market's growth trajectory.

Breakup by End User:

Hospitals and Clinics

Research and Academic Laboratories

Others

Hospitals and clinics dominate the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, research and academic laboratories, and others. According to the report, hospitals and clinics represented the largest segment.

The hospitals and clinics segment dominates the market due to the increasing demand for quality healthcare services and medical interventions. Hospitals and clinics serve as primary access points for medical care, catering to a wide range of medical needs from routine check-ups to specialized treatments. Additionally, advancements in medical technology and treatments drive the need for modern and well-equipped healthcare facilities. Patients seek out hospitals and clinics that offer cutting-edge diagnostic and treatment options, thus encouraging the growth of this segment. Moreover, the growing aging population contributes significantly to the demand for healthcare services. As elderly individuals require more frequent medical attention, hospitals and clinics play a crucial role in providing geriatric care. Furthermore, the rise in chronic diseases necessitates ongoing medical care and management, prompting a greater reliance on hospitals and clinics for continuous patient support.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The North American cholera vaccines market is stimulated by a solid healthcare framework and an emphasis on disease prevention, with stringent public health policies and high awareness increasing demand. International travel and trade further necessitate vaccination. In Asia Pacific, rising cholera outbreaks, lack of sanitation, government efforts, population density, and tourism focus attention on vaccination. Europe's market is propelled by strong healthcare systems and proactive disease surveillance, while travel and trade accentuate the requirement for vaccination. Latin America's growth is due to uneven access to sanitation and government campaigns. In the Middle East and Africa, erratic sanitation infrastructure and recurring cholera outbreaks necessitate vaccines, with governmental and international efforts addressing waterborne diseases.

Competitive Landscape:

The competitive landscape within the market for cholera vaccine is characterized by a dynamic interplay of various factors that shape the positioning of key players. Market participants engage in a multitude of strategies to gain a competitive edge, including product innovation, strategic collaborations, geographical expansion, and mergers and acquisitions. The quest to capture larger market shares and establish brand prominence drives companies to invest in research and development, aiming to offer novel solutions that cater to evolving consumer needs. Furthermore, the emphasis on customer-centric approaches and effective marketing strategies is pivotal in differentiating brands in a crowded marketplace. Regulatory compliance and adherence to industry standards also contribute to the competitive dynamics. The competitive landscape is ever evolving, with players continuously adapting to market trends, customer preferences, and technological advancements to maintain their relevance and sustain growth in this competitive arena.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Astellas Pharma Inc.

Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)

Emergent BioSolutions Inc.

Eubiologics Co. Ltd.

Johnson & Johnson

Merck & Co. Inc.

Pfizer Inc.

PharmaChoice Canada Inc.

Sanofi S.A.

Takeda Pharmaceutical Company Limited

Valneva SE

Recent Developments:

In June 2022, Sanofi unveiled the initiation of its first Digital Accelerator, a significant step that aligns with its aspiration to evolve into a top-tier digital healthcare company.

Key Questions Answered in This Report

  • 1. What was the size of the global cholera vaccines market in 2023?
  • 2. What is the expected growth rate of the global cholera vaccines market during 2024-2032?
  • 3. What are the key factors driving the global cholera vaccines market?
  • 4. What has been the impact of COVID-19 on the global cholera vaccines market?
  • 5. What is the breakup of the global cholera vaccines market based on the vaccine type?
  • 6. What is the breakup of the global cholera vaccines market based on the product?
  • 7. What is the breakup of the global cholera vaccines market based on the end user?
  • 8. What are the key regions in the global cholera vaccines market?
  • 9. Who are the key players/companies in the global cholera vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cholera Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Whole Cell V. Cholerae O1 with Recombinant B-Subunit
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Killed Oral O1 and O139
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Dukoral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Shanchol
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Vaxchora
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Euvichol and Euvichol-Plus
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research and Academic Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Astellas Pharma Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Emergent BioSolutions Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eubiologics Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Johnson & Johnson
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 PharmaChoice Canada Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Takeda Pharmaceutical Company Limited.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Valneva SE
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials